Results 91 to 100 of about 2,752 (194)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

International Journal of COPD, 2017
James F Donohue,1 Keith A Betts,2 Ella Xiaoyan Du,2 Pablo Altman,3 Pankaj Goyal,4 Dorothy L Keininger,4 Jean-Bernard Gruenberger,4 James E Signorovitch5 1Department of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina ...
Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE   +7 more
doaj  

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers

, 2014
Indacaterol is an inhaled, ultra-long-acting β2-agonist that provides 24-h bronchodilation with once-daily dosing in patients with chronic obstructive pulmonary disorder.
Hu, Pei, Li, Lilly, Yin, Hequn, Li, Ruobing, Emotte, Corinne, Jiang, Ji, Woessner, Ralph, Khindri, Sanjeev   +7 more
core   +1 more source

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

International Journal of COPD, 2018
Kai Michael Beeh,1 Anne-Marie Kirsten,2 Ana-Maria Tanase,3 Alexia Richard,3 Weihua Cao,4 Bettina Hederer,3 Jutta Beier,1 Oliver Kornmann,5 Richard N van Zyl-Smit6 1Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany; 2Pulmonary Research ...
Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN   +8 more
doaj  

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study

, 2019
Alan Kaplan,1 Kenneth R Chapman,2 Syed M Anees,3 Irvin Mayers,4 Driss Rochdi,5 Michel Djandji,5 David Préfontaine,5 Andrew McIvor6 1Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada; 2Division of Respiratory ...
Préfontaine D, Kaplan A, Anees SM, Djandji M, Rochdi D, Chapman KR, Mayers I, McIvor A   +7 more
core  

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

, 2015
Nobuyuki Horita, Takeshi Kaneko Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan Abstract: Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device ...
Horita N, Kaneko T
core  

Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma

, 2007
The present study examined the bronchodilator and safety profiles of single-dose indacaterol in intermittent or persistent asthma. In the present double-blind crossover study, 42 patients were randomised to receive single doses of indacaterol (50, 100 ...
Kanniess, Frank, van As, A, Beeh, Kai M, Higgins, M, Cameron, Ray, Derom, Eric   +5 more
core   +1 more source

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in patients with COPD

, 2011
Indacaterol is a novel, inhaled once-daily ultra long-acting β2-agonist for the treatment of COPD. This randomised, double-blind, placebo-controlled, two-period crossover study evaluated the effect of two-week treatment with indacaterol 300 μg on peak ...
Drollmann, Anton Franz, Anton Franz Drollmann, Frank Wagner, Sanjeev Khindri, beeh, kai, Khindri, Sanjeev, Kai-Michael Beeh, wagner, frank   +7 more
core   +1 more source

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]

International Journal of COPD, 2018
Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. International Journal of Chronic Obstructive Pulmonary Disease. 2017; 12:3469—3485. Page 3481, right column, last paragraph, line 3, the text “(fromoterol and indacaterol)&rdquo ...
Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L   +4 more
doaj  

Eficacia del indacaterol como broncodilatador en un grupo de pacientes asmáticos

Revista Cubana de Medicina
La búsqueda de nuevas opciones terapéuticas para tratar las enfermedades obstructivas bronquiales representa un reto permanente y los broncodilatadores constituyen unos de los fármacos más empleados para la atención de estos pacientes.
Juan Carlos Rodríguez Vázquez, Licet Zambrano Mendoza, Carlos Gassiot Nuño, Pedro Pablo Pino Alfonso, Ailema Lima Guerra, Lixaida Cabanes Varona, Lisvenia Morales Sánchez, Adela Ramos Quevedo   +7 more
doaj  

[Indacaterol is a new once-daily beta2-agonist for treatment of COPD]

, 2010
The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist.
Ulrik, Charlotte Suppli
core   +1 more source